ImageBAT™
Cancer Prognosis / Patient Stratification
Key Facts
About Adiposs
Adiposs is pioneering a novel diagnostic imaging platform focused on brown adipose tissue (BAT), a metabolically active fat with significant implications for metabolic diseases and oncology. Its lead candidate, ImageBAT™, is a first-in-class contrast agent that has completed a Phase I clinical trial and is poised for proof-of-principle studies following a CHF 4 million Series A round. The company, led by an experienced team of biotech entrepreneurs, is targeting a significant unmet need in functional metabolic imaging, with potential applications in patient stratification, treatment monitoring, and therapeutic development across multiple disease areas.
View full company profileAbout Adiposs
Adiposs is pioneering a novel diagnostic imaging platform focused on brown adipose tissue (BAT), a metabolically active fat with significant implications for metabolic diseases and oncology. Its lead candidate, ImageBAT™, is a first-in-class contrast agent that has completed a Phase I clinical trial and is poised for proof-of-principle studies following a CHF 4 million Series A round. The company, led by an experienced team of biotech entrepreneurs, is targeting a significant unmet need in functional metabolic imaging, with potential applications in patient stratification, treatment monitoring, and therapeutic development across multiple disease areas.
View full company profileAbout Adiposs
Adiposs is pioneering a novel diagnostic imaging platform focused on brown adipose tissue (BAT), a metabolically active fat with significant implications for metabolic diseases and oncology. Its lead candidate, ImageBAT™, is a first-in-class contrast agent that has completed a Phase I clinical trial and is poised for proof-of-principle studies following a CHF 4 million Series A round. The company, led by an experienced team of biotech entrepreneurs, is targeting a significant unmet need in functional metabolic imaging, with potential applications in patient stratification, treatment monitoring, and therapeutic development across multiple disease areas.
View full company profile